AecorBio is an IND-stage biopharmaceutical company based in Menlo Park, California.
AecorBio has developed a novel high-throughput peptide drug discovery platform that targets multiple drug resistance mechanisms across oncology, immunology and neurology.
Drug treatment resistance is the defining unmet need across three of the largest pharmaceutical markets — oncology ($256B), immunology ($112B), and neurology ($90B).
AecorBio's novel peptide platform has discovered lead drug candidates addressing treatment resistance across all three verticals.
Our managed services operating model is lean, capital-efficient, and built for speed, with world-class partners across discovery, preclinical CRO, CMC and regulatory strategy.
AecorBio's first IND-enabling drug candidate — FT-002a — targets AR-treatment resistance in prostate cancer (CRPC).
Lead Drug Candidate · FT-002a
First-in-class peptide therapy targeting the iron mechanism behind cancer treatment resistance.
AecorBio has discovered a novel peptide drug (FT-002a) that restores androgen receptor inhibitor drug sensitivity in Castration Resistant Prostate Cancer.
FT-002a targets the labile iron pool (LIP) — a validated but previously undruggable resistance mechanism.
AecorBio is advancing FT-002a, a patented, orally available peptide co-therapeutic, toward IND filing to treat advanced prostate cancer.
78%
Reduction in CRPC tumors vs
Androgen Receptor Inhibitor (SOC) alone
Androgen Receptor Inhibitor (SOC) alone
0
Approved Therapies
in This Space
in This Space
$13B+
CRPC Market
Annual Sales
Annual Sales
Science & Data
The iron gene dysregulation story
1
Tumors hijack iron to resist therapy
Treatment-resistant cancers chronically elevate their labile iron pool (LIP) — the free intracellular Fe²⁺ reservoir — fuelling tumor survival and blocking therapy-induced cell death.
2
One gene (IREB2) orchestrates the hijack
The IREB2 gene is the master iron regulatory switch. When dysregulated by the tumor cell, it simultaneously drives up iron uptake (TFRC↑), blocks safe storage (FTH1↓), and suppresses export (FPN↓).
The result: a chronically iron-overloaded LIP that protects tumors.
The result: a chronically iron-overloaded LIP that protects tumors.
3
Our FT-002a drug normalizes IREB2 gene expression
FT-002a downregulates the dysregulated IREB2 gene, simultaneously correcting all three downstream iron regulators. The LIP normalizes — starving the tumor of the extra free iron it needs to help escape ARI therapy.
4
Resistance reversed. SOC restored.
By normalizing the dysregulated LIP, FT-002a re-sensitizes treatment-resistant tumors to frontline ARI drugs — without toxicity and without disrupting systemic iron homeostasis.
Successful clinical intervention
78%
Tumor volume reduction vs. enzalutamide alone in a 46-day AR-resistant PC3 orthotopic CRPC model. Clear dose response confirmed at 20, 40 and 80 mg/kg mouse oral dosing.
No toxicity at any dose tested.
No toxicity at any dose tested.
96%
Tumor volume reduction in AR-sensitive VCaP orthotopic PC model
2,000
mg/kg/day NOAEL — 7 day SD rat repeat-dose study.
No adverse findings.
No adverse findings.
29
Differentially expressed onco-proteins confirmed by proteomics
Bottom line
Novel biology. Novel chemistry. Reproducible efficacy in multiple independent animal models. Clean safety through NOAEL. Stage: IND-enabling with Stanford University clinical collaboration.
A first-in-class oral combination therapy in a $10B+ market with no approved competitors.
A first-in-class oral combination therapy in a $10B+ market with no approved competitors.
FT-002a Commercial Opportunity
Combination drug therapy is the emerging paradigm
Lead Indication · Prostate Cancer
$13.5B
Global CRPC treatment market in 2025 — projected to reach $33B by 2035 at 9.5% CAGR, driven by ARI adoption and combination therapy strategies.
Why FT-002a fits now
Androgen receptor inhibitors (enzalutamide, abiraterone, apalutamide, darolutamide) are the backbone of CRPC treatment — yet all patients ultimately develop resistance. Combination therapies pairing ARIs with novel mechanisms are the dominant clinical and commercial direction across J&J, Pfizer, Astellas and Novartis. FT-002a is designed as an oral co-treatment that restores ARI sensitivity through a mechanism no approved drug addresses.
~34.5%
ARI segment share of global CRPC market — the single largest therapeutic class
0
Approved therapies specifically targeting treatment resistance via the iron/LIP pathway
Second Indication · Ovarian Cancer
$4.1B
Ovarian cancer treatment market in 2024 — growing at a 24.1% CAGR through 2034, with platinum-resistant disease representing the largest unmet need.
The platinum resistance problem
Around 70% of ovarian cancer patients relapse within 3 years of first-line platinum-based chemotherapy. Outcomes in platinum-resistant disease are poor and options are severely limited — no approved therapy has shown a meaningful overall survival benefit beyond bevacizumab. AecorBio's LIP-normalization approach addresses the iron-dependent survival pathway that underpins cisplatin resistance — a mechanistically novel strategy in a space with high clinical urgency.
Combined addressable opportunity
Two high-value oncology markets. One oral peptide platform. Co-treatment positioning means no displacement of existing blockbuster drugs — FT-002a is additive to the standard of care, lowering the commercial adoption barrier and enabling partnership with existing ARI franchise holders.
Pipeline
First lead asset at IND-enabling stage — three programs in pre-clinical development.
Lead Asset · Oncology
FT-002a-O
Castration-Resistant Prostate Cancer (CRPC)
Co-treatment with frontline ADT drugs
IND-Enabling
Co-treatment with frontline ADT drugs
Oral peptide that normalizes IREB2-driven iron dysregulation in treatment-resistant
prostate tumors, restoring sensitivity to androgen deprivation therapy.
78% resistant tumor reduction vs. SOC alone. Clean safety profile at all doses tested.
Tumor reduction vs. enzalutamide alone
78%
NOAEL (rat, repeat dose)
2,000 mg/kg/day
Oral bioavailability
~30%
IND Approval Target
Q1 2027
Phase 1b completion Q1 2028
Oncology
FT-002a-O
Platinum-Resistant Ovarian Cancer Co-treatment
Preclinical
Label extension of the same MOA — iron normalization — applied to platinum resistance in ovarian cancer.
IND Approval Target: Q3 2027
Immunology
MA-022s
Steroid-Resistant Asthma & Eosinophilic esophagitis (EoE)
Preclinical
Novel Lipopeptide Lead Drug Candidate. Dual mechanism — eosinophilia and non-T2 inflammatory pathways.
IND Approval Target: Q2 2027
Neurology
Peptide-DRD2
Dopamine agonist augmentation co-treatment targeting Restless Leg Syndrome & Parkinson's Disease
Optimization
Novel peptide for DRD2 gene upregulation.
IND Approval Target: Q2 2028
Novel Discovery Platform
Step 1
Targeted protein hydrolysis
Enzymatic proteolysis of single proteome sources generates 10,000+ unique peptides per library
→
Step 2
Unique peptide sequences
Novel scaffolds screened directly against gene expression targets — not binding affinity
→
Step 3
Gene expression regulation
Active hits refined through analogue synthesis into IP-protected drug lead candidates
Novel Scaffold Class
SPH-derived peptides represent a chemically distinct scaffold not found in synthetic drug libraries — conferring inherent novelty and IP defensibility.
Gene Expression Targeting
Hits are identified by measuring gene expression modulation directly — not binding affinity. This captures on-target biology invisible to conventional screening.
High-Throughput Discovery
Each proteome source generates 10,000+ diverse overlapping peptides per library. Hundreds of libraries screened simultaneously — compressing drug development time dramatically.
Platform Versatility
The same platform has already yielded lead compounds across oncology, immunology and neurology — demonstrating genuine multi-indication generativity.
Leadership Team
Deep expertise across drug discovery, oncology and clinical development.
Dr. Bomi Framroze
Ph.D. · CEO & Co-Founder
33+ years in health sciences & biotech. Led discovery programs yielding 80+ patents. Prior C-level roles in oncology & immunology.
Prof. Dr. Karl Sylvester
Head of Clinical Development
20+ years in pediatric surgery & translational science. Led Stanford strategy, advising biotechs on clinical pipelines.
Prof. Dr. Stephen Sonis
Scientific Advisor
300+ publications, cited 35,000+ times. Harvard & Dana-Farber Cancer Institute.
Dr. Crawford Currie
MD, MBA · Head of Medical Research
20+ years across clinical practice, pharma & finance. NHS surgeon, oncology lead. MBA Cranfield.
James Berger
Head of Partnerships & Alliances
23+ years in financial services, biotech & aquaculture. Led global capital markets strategy at HBC.
Partner with AecorBio Inc.
We are interested in co-development partnerships and investors aligned with our programs and IND timelines.
Email us at info@aecorbio.com to learn more